Data from many studies support that mineralocorticoid receptor overactivation plays a crucial role in the development and progression of CVD, CKD and diabetes, through inflammation and fibrosis, which are improved with MRA administration [31]. This evidence concerns the gene NR3C2 and chronic kidney disease.